GREY:VIVXF - Post by User
Post by
StoneMan45on Mar 21, 2020 10:11am
163 Views
Post# 30833139
could be a fairly fast launch with no drug approvals req
could be a fairly fast launch with no drug approvals reqAvivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products that safely support immune function and dampen inflammation, thereby supporting general health and well-being, announces today that it is accelerating its plans for commercial launch of its OxC-Beta product as a supplement for human use in response to the COVID-19 pandemic. OxC-beta is a patent protected product that first launched commercially in livestock applications to help remove antibiotics as growth promoters from the food chain, subsequently launched in the companion animal market as a supplement and is now being readied to launch in the US market, initially, for human use as a health supplement. We will provide updates through additional press releases as the product gets closer to an official commercial launch date and product availability.
page 20.
'No drug app[rovals required'
'Natural product category similar to Omega-3'
https://www.avivagen.com/wp-content/uploads/2020AlphaNorth-Conference.pdf
https://web.tmxmoney.com/article.php?newsid=7189422301857066&qm_symbol=VIV